Aligos Therapeutics Inc (ALGS)
0.80
-0.03
(-3.50%)
USD |
NASDAQ |
Apr 25, 16:00
0.8012
0.00 (0.00%)
After-Hours: 20:00
Aligos Therapeutics Cash from Investing (TTM): 44.98M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 44.98M |
| September 30, 2023 | 56.59M |
| June 30, 2023 | 89.08M |
| March 31, 2023 | 54.10M |
| December 31, 2022 | -26.29M |
| September 30, 2022 | -54.38M |
| June 30, 2022 | -86.90M |
| Date | Value |
|---|---|
| March 31, 2022 | -67.08M |
| December 31, 2021 | 3.022M |
| September 30, 2021 | 34.44M |
| June 30, 2021 | 61.13M |
| March 31, 2021 | 66.22M |
| December 31, 2020 | 32.76M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-86.90M
Minimum
Jun 2022
89.08M
Maximum
Jun 2023
15.98M
Average
34.44M
Median
Sep 2021
Cash from Investing (TTM) Benchmarks
| Mirum Pharmaceuticals Inc | -107.20M |
| CEL-SCI Corp | -0.3835M |
| AIM ImmunoTech Inc | -0.832M |
| IGC Pharma Inc | -0.236M |
| NovaBay Pharmaceuticals Inc | -0.019M |